Nab-paclitaxel (Abraxane®)

Assessment Status Assessment Process Complete
Drug Nab-paclitaxel
Brand Abraxane®
Indication In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.
Assessment Process
Rapid review commissioned 23/01/2014
Rapid review completed 02/03/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full pharmacoeconomic assessment commissioned by HSE 23/05/2014
NCPE assessment completed 05/09/2014
NCPE assessment outcome Reimbursement not recommended

Technical Summary

The NCPE do not recommend reimbursement of nab-paclitaxel (Abraxane®).

The HSE has approved reimbursement following confidential price negotiations December 2015